Trial Profile
Evaluation of the Safety, Pharmacokinetics and Efficacy of Three Doses of YN968D1 in Subjects With Solid Tumors.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Breast cancer; Colorectal cancer; Gastric cancer; Gastrointestinal stromal tumours; Non-small cell lung cancer; Renal cell carcinoma; Solid tumours
- Focus Adverse reactions
- Sponsors Elevar Therapeutics
- 11 Oct 2016 Results assessing preliminary efficacy and safety of apatinib in advanced solid tumors (n=30) presented at the 41st European Society for Medical Oncology Congress.
- 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
- 13 May 2015 Status changed from recruiting to completed as per ClinicalTrials.gov record.